  
AN OPEN -LABEL, PI[INVESTIGATOR_72001] O F DARATUMUMAB SC IN PATIENTS WITH 
MILD TO MODERATE ALZ HEIMER'S DISEASE  (DAR ZAD) 
Protocol Number: 54767414ALZ001  
Principal Investigator:  [INVESTIGATOR_309732] L. Gordon, MD  
Sponsor: Northwell Health  
IND #: (pending)  
Funding and Study Medication  Provided by [CONTACT_48824], LLC  
Version Number:  1.1 
25 April 2019  
  
DARZAD Protocol – Version 1.1    25 APR 2019 ii Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
1. PROTOCOL SUMM ARY  ................................ ................................ ................................ ...............................  1 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  1 
1.2 Schema  ................................ ................................ ................................ ................................ .................  3 
1.3 Schedule of Activities (SoA)  ................................ ................................ ................................ ...............  4 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  4 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .... 4 
2.2 Background ................................ ................................ ................................ ................................ ...........  5 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ....................  5 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ..... 5 
2.3.2  Known Potential Benefits  ................................ ................................ ................................  8 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ................................  9 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ................  9 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ ...........  11 
4.1 Overall Design  ................................ ................................ ................................ ................................ .... 11 
4.2 Scientific Rationale for Study Design ................................ ................................ ..............................  11 
4.3 Justific ation for Dose  ................................ ................................ ................................ .........................  11 
4.4 End of Study Definition  ................................ ................................ ................................ .....................  12 
5 STUDY POPULATION  ................................ ................................ ................................ ................................  12 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................  12 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...............................  13 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ....................  14 
5.4 Screen Failures  ................................ ................................ ................................ ................................ .. 14 
5.5 Strategies for Recruitment and Retention  ................................ ................................ ......................  15 
6 STUDY INTERVENTION  ................................ ................................ ................................ ............................  15 
6.1 Study Intervention Administration ................................ ................................ ................................ .... 15 
6.1.1  Study Intervention Description  ................................ ................................ .....................  15 
6.1.2  Dosing and Administration  ................................ ................................ ............................  15 
6.1.3  CONCURRENT PROTOCOL -SPECIFIC MEDICATIONS  ................................ ...... 15 
6.1.4  MANAGEMENT OF LOCAL INJECTION SITE REACTIONS  ................................ . 16 
6.1.5  MANAGEMENT OF SYSTEMIC INJECTION -RELATED REACTIONS  ................  16 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ................  [ADDRESS_1090264] Storage and Stability  ................................ ................................ .......................  17 
6.2.4  Preparation  ................................ ................................ ................................ ......................  17 
6.2.5  ADMINISTRation  ................................ ................................ ................................ ............  18 
6.3 Measures to Minimize Bias: Randomization a nd Blinding  ................................ ...........................  19 
6.4 Study Intervention Compliance  ................................ ................................ ................................ ........  19 
6.5 Concomitant Therapy  ................................ ................................ ................................ ........................  19 
6.5.1  Rescue Medicine  ................................ ................................ ................................ ............  20 
7 STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  .....................  20 
7.1 Discontinuation of Study Intervention  ................................ ................................ .............................  20 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  [ADDRESS_1090265] to Follow -Up ................................ ................................ ................................ ...............................  21 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ .....................  22 
  
DARZAD Protocol – Version 1.1    25 APR 2019 iii 8.1 Efficacy Assessments  ................................ ................................ ................................ .......................  22 
8.2 Safety and Other Assessments  ................................ ................................ ................................ .......  23 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  24 
8.3.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  24 
8.3.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  [ADDRESS_1090266] Quality ComplaintS (PQC)  ................................ ......................  30 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  31 
8.4.1  Definitio n of Unanticipated Problems (UP)  ................................ ................................ . 31 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ................  32 
8.4.3  Reporting Unanticipated Problems to Participants  ................................ ...................  32 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  32 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  32 
9.2 Sample Size Dete rmination  ................................ ................................ ................................ ..............  34 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  34 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  35 
9.4.1  General Approach  ................................ ................................ ................................ ..........  35 
9.4.2  Analysis of the Primary Efficacy Endpoint  ................................ ................................ .. 35 
9.4.3  Analysis of the Secondary Endpoints  ................................ ................................ .........  35 
9.4.4  Safety Analyses  ................................ ................................ ................................ ..............  35 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ .....................  36 
9.4.6  Planned Interim Analyses  ................................ ................................ .............................  36 
9.4.7  Sub-Group Analyses  ................................ ................................ ................................ ..... 36 
9.4.8  Tabulation of Individual participant Data  ................................ ................................ .... 36 
9.4.9 TERTIARY/Exploratory Analyses  ................................ ................................ ................  [ADDRESS_1090267] Policy  ................................ ................................ ..............................  43 
10.2  Additiona l Considerations  ................................ ................................ ................................ .................  44 
10.3  Abbreviations  ................................ ................................ ................................ ................................ ...... 45 
  
DARZAD Protocol – Version 1.1    25 APR 2019 iv 10.4  Protocol Amendment History  ................................ ................................ ................................ ...........  47 
11 REFERENCES  ................................ ................................ ................................ ................................ .............  48 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  1 
 STATEMENT OF COMPLIA NCE  
 
The trial will be conducted in accordance with I nternational Conference on Harmonisation  Good Clinical 
Practice ( ICH GCP)  and applicable  [LOCATION_002] (US) Code of Federal Regulations  (CFR) . The Principal 
Investigator (PI) will assure that n o deviation from, or changes to  the protocol will take place without 
prior agreement from the Investigational New Drug (IND)  sponsor  and funding agency , and documented 
approval from the Institutional  Review Board ( IRB), except where necessary to eliminate immediate 
hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed 
Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent forms , recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval.  Approval of both the protocol and the consent form must 
be obtained before any participant is enrolled.  Any amendment to the protocol will requir e review and 
approval by [CONTACT_3484].  All changes to the consent form 
will be IRB approved; a determination will be made regarding whether  a new consent needs to be 
obtained from participants who provided consen t, using a previously  approved consent form . 
1.  PROTOCOL SUMMARY  
1.1 SYNOPSIS   
 
Title:   
An open -label, pi[INVESTIGATOR_790938]'s disease  
 
Study Des cription : This is an open -label single site pi[INVESTIGATOR_790939] a clinically meaningful  efficacy signal in patients 
with mild to moderate Alzheimer's disease.  
 
Objectives:  
 SPECIFIC AIM: To estimate the proportion of patients with mild to 
moderate  Alzheimer’s disease who respon d to daratumumab.  A patient 
will be considered a responder if they improve by a minimum of 4 points 
on the ADAS -cog/11 from baseline at 25 weeks . 
  
  
Endpoint s: PRIMARY ENDPOINT:  
Responder rate defined as improvement in standard 11 -item Alzheimer's 
Disease Assessment Scale -cognitive subscale (ADAS -cog/11) score of ≥ 4 
points at 25 weeks  compared with baseline  
 
SECONDARY ENDPOINTS:  
- The proportion of subjects who are unchanged or improved  from 
baseline at 25 weeks  in ADAS -cog/12 score (standard [ADDRESS_1090268] recall)  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  2 
 - The proportion of subjects who are unchanged or improved  from 
baseline at 25 weeks  in Mini -Mental State Examination (MMSE) score  
- The proportion of subjects who are unchanged or improved  from 
baseline at 25 weeks  in Clinical D ementia Rating Scale Sum of Boxes (CDR -
SB) score  
- The proportion of subjects who are unchanged or improved  from 
baseline at 25 weeks  in AD Composite Score  (ADCOMS),  a composite score 
derived from a weighted combination of selected items from the A DAS-
cog/ 12, MMSE, and CDR -SB 
- The proportion of subjects with tre atment -emergent adverse effects  
- The proportion of subjects with treatment -emergent serious  adverse 
effects  
 
TERTIARY/ EXPLORATORY ENDPOINTS:  
- Pattern of change over time at baseline, 12 weeks , 25 weeks , and 36 
weeks  (12 weeks  after completion of treatment) in the following cognitive 
outcome measures: ADAS -cog/11 , ADAS -cog/[ADDRESS_1090269] -SB, ADCOMS  
- Change from baseline at 25 weeks  in CD38 expression on circulating 
(whole blood) CD8+ T -cells measure d with flow cytometry  
- Change from baseline at 25 weeks  in metabolite ratios [ N-acetylaspartate  
(NAA) /creatine (Cr), myo -inositol  (mI)/Cr, choline  (Cho) /Cr, and NAA/mI ] 
on single -voxel proton  magnetic resonance spectroscopy from the 
precuneus and posterior  cingulate region  
 
Study Population:  Male or fema le subjects age ≥ 55 to ≤ 85 years  with a diagnosis of 
probable Alzheimer's disease  dementia according to National Institute on 
Aging -Alzheimer’s Association (NIA -AA) criteria  (McKhann et al. 2011) and 
a Mini -Mental State Examination (MMSE) score of ≥ 15 and ≤ 26 at the 
screening visit  
 
Phase:  2a 
 
Description of 
Sites /Facilities  Enrolling 
Participants :  
This is a single -site study being conducted at the Litwin -Zucker Center, 
Feinstein Institute for Medical Research, [ADDRESS_1090270], 4th floor, 
Manhasset, NY [ZIP_CODE]    
 
Description of Study  
Intervention :  
During the treatment phase, eligible subjects will receive daratumumab SC 
1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) 
subcutaneous infusion  over 3 -5 minutes (15 mL) once weekly for 8 weeks 
followed by [CONTACT_790960] 1800 mg every 2 weeks for 16 weeks.  
 
Study Duration:  24 months  
 
Participa nt Duration:  Up to 44 weeks  (including screening period)   
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  3 
   
1.2 SCHEMA  
  
Day -60 to Day -1 
Screening procedures, baseline MR I 
and cognitive testing  
Visit 1, Day 1  
throu  
Visit 9, Day 64+/ -2 and Visit 10, Day 78+/ -2 
 Daratumumab SC 1800 mg  
every 2 weeks  
  
Visit 11, Day 85+/ -2 
 Interim cognitive testing  
Visit 12, Day 92+/ -2 to Visit 17, Day 162+/ -2  
 daratumumab SC 1800 mg  
every 2 weeks  
Visit 18, Day 176+/ -3 
Endpoint cognitive testing, MRI, 
and flow cytometry  
Visit 19, Day 246+/ -7 
 Follow -up cognitive testing  Daratumumab SC 1800 mg  weekly  Visit 2, Day 8 +/ -1 to Visit 8, Day 50+/ -1 
throu  
Baseline flow cytometry, type and 
screen, initial infusion of 
daratumumab SC 1800 mg  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  4 
 1.3 SCHEDULE OF ACTIVITIES (SOA)  
    
Procedures  
Screening  
Day -60 to -1 
Baseline  
Visit 1, Day 1  
Study Visit 2  
Day 8 +/ -1 day  
Study Visit 3  
Day 15 +/ - 1 day  
Study Visit 4  
Day 22 +/ -1 day  
Study Visit 5  
Day 29 +/ -1 day  
Study Visit 6  
Day  36 +/ -1 day  
Study Visit 7  
Day 43 +/ -1 day  
Study Visit 8  
Day 50 +/ -1 day  
Study Visit 9  
Day 64 +/ -2 days  
Study Visit 10  
Day 78 +/ -2 days  
Study Visit 11  
Day 85 +/ - 2 days  
Study Visit 12  
Day 92 +/ -2 days  
Study Visit 13  
Day 106 +/ -2 days  
Study Visit 14  
Day 120 +/ -2 days  
Study Visit 15  
Day 134 +/ -2 days  
Study Visit 16  
Day 148148 -2 days  
Study Visit 17  
Day 162 +/ -2 days  
Study Visi t 18 
Day 176 +/ -3 days  
Final Study Visit 19  
Day 246 +/-7 days  
Informed consent  X                    
Demographics  X                    
Medical history  X                    
Administer daratumumab  SC  X X X X X X X X X X  X X X X X X   
Physical and neur o exam   X           X       X X 
Vital signs  X X X X X X X X X X X X X X X X X X X X 
Height  X                    
Weight  X X X X X X X X X X X  X X X X X X X X 
12-lead ECG  X                    
CBC  X  X X X X X X X X X  X X X X X X  X 
Comprehensive met abolic 
panel  X    X     X  X      X  X  X  X 
PT/INR, APTT, TSH, B12 level  X                    
Hepatitis B surface antigen 
and core antibody  X                    
Hepatitis C Virus a ntibody  X                    
HIV antigen/antibody  screen  X                    
Brain MRI  X                  X  
Amyloid PET scan of brain  X                    
Type and screen   X                   
Flow cytometry   X                 X  
Concomitant medications  X X X X X X X X X X X X X X X X X X X X 
Adverse events review   X X X X X X X X X X X X X X X X X X X 
Modified Hachinski  (MHIS)  X                    
GDS X                    
CDR X           X       X X 
MMSE  X           X       X X 
ADAS -Cog X           X       X X 
 
2  INTRODUCTION  
 
2.1 STUDY R ATIONALE   
 
Alzheimer’s disease  (AD) is a gradually progressive neurodegenerative disease that is the leading cause 
of dementia world -wide. Currently available treatments for AD, which include cholinesterase inhibitors 
(donepezil, rivastigmine, and galantamine) and a low -affinity NMDA r eceptor antagonist (memantine), 
have only modest effects on the symptoms of the disease, and do not prevent disease progression. 
While the underlying cause of Alzheimer’s disease remains unknown, there has been extensive evidence 
that mitochondrial dysfunc tion (Perez Ortiz and Swerdlow 2019)  and neuroinflammation (Heneka et al. 
2015) play a significant role in the pathogenesis of AD.  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  5 
 Nicotinamide adenine dinucleotide (NAD) is a co -enzyme found in all living cells. NAD levels decrease 
during aging and are i nvolved in age -related metabolic decline  (Imai and  Guarante  2014, Verdin 2015) . 
CD38 is a multi -functional enzyme that hydrolyzes NAD, and is also involved in cell signaling. CD38 levels 
increase in tissues with age and correlate with NAD decline  (Camacho -Pereira et al.  2016)   In CD38 
knockout mice, tissue levels of NAD are significantly increased  (Askoy et al.  2006) . When CD38 knockout 
mice were crossed with APPswePS1ΔE9  transgenic mice  to generate Alzheimer’s pathology -prone CD38 -
deficient mice, they  exhibited significant reductions in amyloid -beta  (Aβ) plaque load and soluble Aβ 
levels, and this correlated with improved spatial learning.  Furthermore, neurona l cultures derived from 
these mice secreted less Aβ , and this reduction was mimicked when APPswePS1ΔE9  neuronal cultures 
were treated with inhibitors that blocked CD38 enzyme activity or the signaling pathways controlled by 
[CONTACT_398]38‐derived metabolites , sugges ting that CD38 may be a novel target for AD treatment  (Blacher et al. 
2015) .  
 
CD38 expression on CD8+ T -cells, indicative of activation, is significantly increased in the blood of early 
AD patients as compared with age -matched controls, and activated T -cells are capable of trafficking into 
the central nervous system and exerting cytotoxic effects  (Zhang et al.  2013) . CD38 significantly affects 
regulation of the amount and function of activated microglia, with important consequences for injury 
and repair pr ocesses in the brain  (Mayo et al.  2008) . 
 
2.[ADDRESS_1090271] -ranging immunomodulatory effects on 
nonplasma cells t hat express CD38  (Krejcik et al.  2016) . Daratumumab is able to cross the blood -brain 
barrier (Vercruyssen  et al. 2018).  
 
A subcutaneous (SC) formulation of daratumumab  with recombinant human hyaluronidase enzyme 
PH20 (rHuPH20) has been shown to be  well tol erated, with low rate s of infusion -related reactions  and 
similar efficacy to intravenous  (IV) daratumumab in patients with multiple myeloma. (Usmani et al . 
2016 , Chari et al. 2018).  Furthermore, each dose of daratumumab SC can be administered over [ADDRESS_1090272], second, and subsequent  IV infusion  durations  of 7.0, 4.3, and 
3.4 hours, respectively . 
 
2.3 RISK/BENEFIT ASSESSM ENT    
   
2.3.1  KNOWN  POTENTIAL RISKS  
  
While the package insert for the IV formulation of daratumumab (Darzalex) i s provided for reference,  it 
should be noted that it includes  data for adverse effects in patients with multiple myeloma who were 
treated with various combination chemotherapy regimens. Furthermore, multiple myeloma is a 
hematological malignancy that can p redispose patients to infection, anemia, thrombocytopenia, and 
leukopenia. As per the package insert, t he safety data reflect ing exposure to IV daratumumab 16 mg/kg  
mon otherapy in 156 adult patients with relapsed and  refractory multiple myeloma treated in  three 
open -label, clinical  trials , with  median duration of exposure of 3.3 months (range: 0.03 to 20.04 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  6 
 months) , are listed below.  Serious  adverse reactions were reported in 51 (33%) patients. The most 
frequent serious adverse  reactions were pneumonia (6% ), general physical health deterioration (3%), 
and pyrexia (3%).  Adverse reactions resulted in treatment delay for 24 (15%) patients, most frequently 
for infections. Adverse reactions resulted in discontinuations for 6 (4%) patients.  Adverse reactions 
occu rring in at least 10% of pa tients are presented in Table 1 . Tabl e 2 describes Grade 3 –4 laboratory 
abnormalities reported at a rate of ≥10%.  
 
Table 1 : Adverse reactions with incidence ≥ 10% in patients with multiple myeloma treated with IV 
daratumumab 16 m g/kg
 
 
Table 2 : Treatment -emergent Grade 3 -4 laboratory abnormalities ( ≥ 10 %) in patients with multiple 
myeloma treated with IV daratumumab 16 mg/kg  

An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  7 
  
 
Infusion Reactions : 
In clinical trials of IV daratumumab (monotherapy and combination treatments; N=116 6) the incidence 
of any grade  infusion reactions was 40% with the first infusion, 2% with the second infusion,  and 4% 
with subsequent infusions. Less than 1% of patients had a Grade 3 infusion reaction with  second or 
subsequent infusions. Grade 4 infusion reactions were reported in 2/1166 (0.2%) of  patients.  
The median time to onset of a reaction was 1.4 hours (range: 0 to 72.8 hours). The incidence of  
infusion modification due to reactions was 37%. Median durations of infusion for the 1st, 2nd , and 
subsequ ent infusions were 7.0, 4.3, and 3.4 hours respectively.  Severe infusion reactions included 
bronchospasm, dyspnea, laryngeal edema, pulmonary edema,  hypoxia, and hypertension. Other adverse 
infusion reactions included nasal congestion, cough,  chills, throa t irritation, vomiting and nausea.  
 
Herpes Zoster Virus Reactivation : 
In IV daratumumab monotherapy studies, herpes zoster was reported in 3% of patients.  
 
Hepatitis B Virus Reactivation : 
As of [ADDRESS_1090273] (indirect Coom bs test) : 
Daratumumab binds to CD38 found at low levels on red blood cells (RBCs) and may result in a  positive 
indirect Coombs test. Daratumumab -mediated positive indirect Coombs test may persist  for up to [ADDRESS_1090274]’s serum. The determination of a 
subject’s ABO and Rh blood type are not impacted.  
 
Daratumumab SC:  
The subcutaneous route of administration  for daratumumab was first evaluated by [CONTACT_790961] 
& Development in Study MMY1004 (PAVO), a Phase 1b, open -label, multicenter, 2 -part dose escalation 
study in patients with relapsed or refractory multiple myeloma. In this ongoing study, daratumum ab SC 
(Dara -SC) is being administered according to the approved monotherapy schedule [i.e., weekly for 8 
weeks, every 2  weeks for an additional 16  weeks, and every 4 weeks thereafter until progressive disease 
(PD) or unacceptable toxicity] . The PAVO study assessed the safety, pharmacokinetics, and efficacy of SC 

An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  8 
 administration of daratumumab plus rHuPH20 (DARA -PH20). After a median follow -up of 6.5  months 
(clinical cutoff date of 13 Dec 2017), [ADDRESS_1090275] 1 dose of 1800  mg Dara -SC in Study  
MMY1004. The injection -related reaction rate was 16% and consisted of Grade  1 or 2 chills, dyspnea, 
sneezing, and allergic rhinitis, and two Grade 3 events of hypertension. None of the injection -related 
reaction events led to treatment discontinuation. In jection -site reactions occurred in 12% (n=3) of 
patients, all were Grade 1. The events were discoloration/injection site induration, hematoma, and 
erythema. The overall response rate (ORR) was 52% with 28% very good partial response rate (VGPR). 
Median pro gression -free survival (PFS) has not been reached. The efficacy and adverse event profile are 
consistent with that of IV daratumumab with a lower rate of injection -related reactions. Based on these 
clinical data and supported by [CONTACT_790962] -SC, the safety and efficacy of Dara -SC 
appear equivalent to and may be better than Dara -IV. Together these findings suggest that co -
formulated SC daratumumab 1800  mg plus rHuPH20 is well tolerated and achieves response rates 
similar to those obser ved with daratumumab administered by [CONTACT_16228]. In addition, the daratumumab 
SC administration has an added benefit of shorter administrati on time (3 to 5 minutes for SC 
daratumumab injection versus a median duration of 7 hours when administered by [CONTACT_790963]).  
Please refer to the Investigator’s Brochure (IB) for more detailed safety data  about daratumumab . 
 
Known potential risks of concurrent  protocol -specific medications:  
 
1. Side effects of dexamethasone  may include nausea, vomiting, heartburn, headach e, dizziness, 
trouble sleepi[INVESTIGATOR_007], appetite changes, increased sweating, high  blood sugar,  mood swings, bleeding 
from the stomach, swelling of the hands or feet, and bone damage.  
2. The most common adverse reactions in adult patients treated with  acetaminophen  (Tylenol) are 
nausea, vomiting, headache, and insomnia . 
3. Side effects of diphenhydramine  (Benadryl) may include sleepi[INVESTIGATOR_008], confusion, dizziness, 
incoordination, dry mouth, blurred vision, upset stomach, constipation, and difficulty urinating.  
4. The most commo n adverse reactions to montelukast (incidence >5% and greater than  placebo , 
listed in descending o rder of frequency) are  upper respi[INVESTIGATOR_4416], fever, headache, 
pharyngitis  (sore throat) , cough, abdominal pain, diarrhea, otitis media  (ear infection) , influenza, 
rhinorrhea  (runny nose) , and sinusitis  (inflammation of sinuses).   
5. Side effects of acyclovir  may include nausea, vomiting, dizziness, diarrhea, sleepi[INVESTIGATOR_008] , and 
confusion.  
 
2.3.2  KNOWN POTENTIAL BENE FITS  
 
While daratumumab is FDA -approved for the tre atment of multiple myeloma, and is under study for the 
treatment of other hematological malignancies, it has not previously been studied for the treatment of 
Alzheimer’s disease. There is a rationale to suggest a potential for direct benefit to AD subjec ts. 
However,  this study is exploratory, and there is no guarantee of direct benefit. The results of this study 
may provide generalizable knowledge about the potential utility of this strategy for the treatment of 
Alzheimer’s disease, and should provide more specific data regarding the benefit -risk ratio of 
daratumumab in this patient population . 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090276] 
(indirect Coombs test) , and mask detection of antibodies to minor antigens in the  subject’s serum , type 
and screen will be sent prior to treatment initiation.  To minimize the risk of post -infusion  reactions, 
individuals with a history of asthma or chronic obstructive pulmonary disease will be exclude d, and 
subjects will be premedicated with montelukast [ADDRESS_1090277] a CBC performed within 48 hours prior to each subsequent 
infusion , and the scheduled infusion  will be held if there  is evidence of clinically significant anemia, 
neutropenia, leukopenia, or thrombocytopenia. Additional safety laboratory monitoring will include a 
comprehensive metabolic panel (CMP) every 4 weeks.  
 
3 OBJECTIVES AND ENDPO INTS  
OBJECTIVES  ENDPOINTS  JUSTIFICAT ION FOR 
ENDPOINT S 
Primary    
To estimate the proportion of 
patients with Alzheimer’s disease 
who have a clinically meaningful  
response to daratumumab  
 
 
 Responder rate defined as 
improvement in standard 11 -item 
Alzheimer's Disease Assessment 
Scale -cogniti ve subscale (ADAS -
cog/11) score of ≥ 4 points at 25 
weeks  compared with baseline  An improvement of ≥ 4 
points in ADAS -cog/11 
score has been 
deemed to be clinically 
meaningful . Based on 
previous results in 
patients with mild to 
moderate AD 
maintained on sta ble 
treatment with a 
cholinesterase 
inhibitor, the expected 
responder rate at 25 
weeks  (defined as 
improvement in ADAS -
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  10 
 OBJECTIVES  ENDPOINTS  JUSTIFICAT ION FOR 
ENDPOINT S 
cog/11 score of ≥ 4 
points) is 20% (0.20).  
Secondary    
To estimate the proportion of 
patients who remain stable 
(unchanged) or improve at 25 
weeks vs baseline on additional 
cognitive outcome measures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To estimate the  proportion of 
subjects with treatment -emergent 
adverse effects and severe adverse 
effects  The proportion of subjects who are 
unchanged or improved  from 
baseline to 25 weeks  in ADAS -cog/12 
score (standard [ADDRESS_1090278] recall)  
 
The proportion of subjects who are 
unchanged or improved  from 
baseline to 25 weeks  in Mini Mental 
State Examination (MMSE) score  
 
The proportion of subjects who are 
unchan ged or improved  from 
baseline to 25 weeks  in Clinical 
Dementia Rating Scale Sum of Boxes 
(CDR -SB) score  
 
The proportion of subjects who are 
unchanged or improved  from 
baseline to 25 weeks  in ADCOMS 
score (a composite score derived 
from a weighted combinati on of 
selected items from the ADAS -
cog/12, MMSE, and CDR -SB) 
 
The proportion of subjects with one 
or more treatment -emergent adverse 
events  
 
The proportion of subjects with one 
or more treatment -emergent  serious  
adverse events  These are other widely 
used c ognitive outcome 
measures in clinical 
trials of patients with 
Alzheimer’s disease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To describe the 
adverse event profile 
of subcutaneous 
daratumumab in 
patients with mild to 
moderate Alzheimer’s 
disease  
 
Tertiary/ Exploratory    
To desc ribe the pattern of change 
over time in response to 
daratumumab on cognitive 
outcome measures  
 
 Change over time at baseline, 12 
weeks, 25 weeks, and 36 weeks (12 
weeks after completion of treatment) 
in the following cognitive outcome 
measures: ADAS -cog/11 , ADAS -
cog/[ADDRESS_1090279]-SB, ADCOMS  To observe the time to 
onset and persistence 
of cognitive responses 
to daratum umab 
 
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  11 
 OBJECTIVES  ENDPOINTS  JUSTIFICAT ION FOR 
ENDPOINT S 
 
 
To measure the effects of 
daratumumab on CD38 expression 
in circulating CD8+ T-cells  
 
 
 
To explore the effects of 
daratumumab on cerebral 
metabolites.   
 
Change from baseline to 25 weeks  in 
CD38 expression on circulatin g 
(whole blood) CD8+ T-cells measured 
with flow cytometry  
 
 
Change from baseline to 25 weeks  in 
metabolite ratios (N -
acetylaspartate/creatine, myo -
inositol/creatine, choline/creatine, 
and N -acetylaspartate/myo -inositol) 
on single -voxel protein magnetic 
resonance spectroscopy from the 
precuneus and posterior cingulate 
region  
  
 
To provide evidence of 
target engagement for 
the putative 
immunological 
mechanism of action  
 
To pr ovide evidence of 
daratumumab effects 
on cerebral 
metabolism  
 
[ADDRESS_1090280] a 
clinically meaningful  efficacy signal in patients with mild to mo derate Alzheimer's disease. During the 
treatment phase, eligible subjects will receive daratumumab SC 1800 mg (daratumumab 1800 mg with 
rHuPH20 30,000 units) subcutaneous infusion  over 3 -5 minutes (15 mL) once weekly for [ADDRESS_1090281] 11 -item Alzheimer's Disease Assessment Scale -cognitive 
subscale (ADAS -Cog/11) score of ≥ 4 points at 25 weeks  compared with baseline . 
 
4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
 
This is a pi[INVESTIGATOR_799], the purpose of which is explore whether there is a clinically meaningful  efficacy 
signal for daratumumab in patients with mild to moderate Alzheimer's disease. The proposed sample 
size of 15 patients is based on feasibility and availability of resources, and not on a formal power 
calculation.  
 
4.3 JUSTIFICATION FOR DO SE 
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090282] scheduled procedure shown in the S chedu le of Activities (SoA), 
Section 1.[ADDRESS_1090283] meet all of the following criteria:  
 
1. Each subject must be ≥ 55 to ≤ [ADDRESS_1090284] a diagnosis of probable AD dementia according to National Institute on 
Aging -Alzheimer’s Associat ion (NIA -AA) criteria.  
3. Each subject must have a Mini -Mental State Examination (MMSE) score ≥ 15 and ≤ [ADDRESS_1090285] a Magnetic Resonance Imaging (MRI) scan performed during  the s creening 
period that is consistent with a diagnosis of AD.  
5. Each subject must have a positive amyloid Positron Emission Tomography (PET) scan , either  
performed during the s creening period, or previously  performed provided that the scan and result 
are considered acceptable by [CONTACT_11168].  
6. If the subject is receiving a cholinesterase inhibitor (donepezil, rivastigmine, or galantamine) and/or 
memantine, the dose must have been stable for at least [ADDRESS_1090286] 3 days/week for a minimum 
of 6 waking hours/week, and be w illing to accompany the subject to all required study  visits . 
8. Each subject must have no clinically significant abnormal laboratory test results [complete blood 
count (CBC), prothrombin time (PT)/international normalized ratio (INR), activated partial 
throm boplastin time (APTT), comprehensive metabolic panel (CMP), thyroid stimulating hormone 
(TSH), and vitamin B12 level] at the screening visit.  
9. Each subject must have results of a physical and neurological examination and vital signs within 
normal limits or clinically acceptable to the investigator at the screening visit.  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090287] be postmenopausal defined as: No menses for 12 or more months 
without an alternative medical cause OR permanently surgically sterile (bilateral oophorectomy, 
bilateral salpi[INVESTIGATOR_1656] , or hysterectomy).  
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study:  
 
1. The subject has a Rosen -modified Hachinski Ischemia Score > [ADDRESS_1090288] has a known history of stroke or evidence from screening MRI that is clinically 
significant in the investigator's opi[INVESTIGATOR_1649].  
3. The subject has evidence of a clinically relevant neurological disorder other th an probable AD  at the 
screening visit, includ ing: vascular dementia, Parkinson’s disease, dementia with Lewy bodies, 
frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, amyotrophic 
lateral sclerosis, Huntington's disease, multiple sclerosis, mental retardation, hypoxic  cerebral 
damage, or head trauma with loss of consciousness that led to persistent cognitive deficits.  
4. The subject has evidence of a clinically relevant or unstable psychiatric disorder, based on DSM -5 
criteria, including schizophrenia or other psychotic d isorder, bipolar disorder, delirium , or major 
depression. (Major depression in remission is not exclusionary.)  A score on the 15 -item Geriatric 
Depression Scale (GDS) of [ADDRESS_1090289] has a history of alcoholism or drug dependency/abuse within the l ast [ADDRESS_1090290] within 60 days or 5 half -lives 
(whichever is longer) prior to the screening visit.  
7. The subject  has been treated with anti -amyloid -beta or anti -tau protein monoclo nal antibodies 
within one year prior to the screening visit.  
8. The subject  has been treated with an active vaccine targeting amyloid -beta or tau protein.  
9. The subject  has received a live/live -attenuated bacterial or viral vaccine within [ADDRESS_1090291]  has a history of asthma or chronic obstructive pul monary disease.  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090292]  has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or 
required intervention for any of these conditions (e.g., coronary artery by[CONTACT_9292], percutaneous 
coronary intervention via cardiac cathete rization, thrombolytic therapy) within [ADDRESS_1090293]  has serologic evidence of current or prior hepatitis B vi rus (HBV) infection based on 
hepatitis B surface antigen or hepatitis core antibody blood tests at the screening visit . 
19. The subject  has serologic evidence of hepatitis C virus (HCV) infection based on hepatitis C antibody 
blood test at the screening visit.  
20. The subject  has serologic evidence of human immunodeficiency virus (HIV) infection based on HIV 
antigen/antibody  test at the screening visit.  
21. The subject  has a platelet count  less than 50,000 per microliter (mL) at the screening visit.  
22. The subject  has a c reatinine clearance less than 30 mL/minute at the screening visit.  
23. The subject  has a history or evidence of a malignancy (except for adequately treated basal cell or 
squamous cell skin cancer, in situ cervical cancer, or localized prostate carcinoma) with in the [ADDRESS_1090294]  has had any other unstable/uncontrolled medical illness within [ADDRESS_1090295]  has significant visual or auditory impairment, or limited English proficiency, that in the 
investigator's opi[INVESTIGATOR_790940].  
26. The subject  has any contraindication to or inability  to tolerate brain MRIs (e.g., a pacemaker or any 
other implanted device or condition that would preclude proximity to a strong magnetic field).  
27. The subject  has any contraindication to or inability to tolerate a PET scan (includes current or 
recent partici pation in any procedures involving radioactive agents such that the total radiation 
dose exposure to the subject in any given year would exceed acceptable limits of annual and total 
dose).  
28. The subject has a history of allergy to dexamethasone, diphenhydram ine, acetaminophen, 
montelukast, or acyclovir.  
 
5.3 LIFESTYLE CONSIDERAT IONS  
 
During this study, participants are asked to a bstain from alcohol for 24 hours before the start of each 
dosing  or cognitive assessment visit.   
 
5.4 SCREEN FAILURES  
 
Screen failures are d efined as participants who consent to participate in the clinical trial but are not 
subsequently assigned to the study intervention or entered in the study. A minimal set of screen failure 
information is required to ensure transparent reporting of screen f ailure participants , to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to 
queries from regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any serious adverse event (SAE).  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  15 
  
Individuals  who do not meet the criteria for participation in this trial (screen failure) because of a n 
MMSE score above  the cutoff of [ADDRESS_1090296] indic ated that they are willing to be contact[CONTACT_34754]. 
We will also screen subjects who are referred by [CONTACT_790964]. We anticipate accrual of 15 subjects over an 18 -month e nrollment 
period. Due to the inherent nature of the study population , with cognitive impairment due to 
Alzheimer’s disease, it is anticipated that many of these subjects will lack decisional capacity to provide 
informed consent. Accordingly, a ll potential subjects will be assessed for capacity to provide informed 
consent by [CONTACT_57618], who are either neurologists or geriatric psychiatrists with 
extensive experience in assessing decisional capacity. If a subject is determined to lack capacit y to 
provide informed consent, surrogate consent will need to be obtained from a legally authorized 
representative. In that instance, the subject  will also need to provide assent to participate in the study.  
 
[ADDRESS_1090297], is a human immunoglobulin G1 kappa  (IgG1κ) monoclonal antibody 
(mAb) that binds CD38 expressing cells with high affinity . The subcutaneous formulation is administered 
in combination with  recombinant human hyaluronidase (rHuPH20 ) to facilitate fluid dispersion.  
6.1.2  DOSING AND ADMINISTR ATION  
 
During the treatment phase, eligible subjects will receive daratumumab SC 1800 mg (daratumumab 
1800 mg with rHuPH20 30,000 units) given through a syringe and needle by a manual push over 
approximately 3 to 5 minutes once weekly for 8 weeks followed by [CONTACT_790965] 1800 mg every 2 
weeks for 16 weeks.  Doses will be administered at alternating locations on the abdomen. The volume of 
1800 mg Daratumumab for SC injection will be approximately 15 mL . In case of significant discomfort 
during manual injection, a slo wer injection speed may be used or alternatively the total dose may be 
given in 2 separate locations.  
6.1.3  CONCURRENT PROTOCOL -SPECIFIC MEDICATIONS  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090298] be treated for their 
symptoms:  
• Treatment with acetaminophen, antihistamine, or co rticosteroids, may be administered as needed.  
• IV saline may be indicated.  
• For bronchospasm, urticaria, or dyspnea, patients may require antihistamines, oxygen, corticosteroids, 
or bronchodilators.  
• For hypotension, patients may require vasopressors .  
 
In the event of a life -threatening reaction (which may include pulmonary or cardiac events) or 
anaphylactic reaction, the patient will be transported to the Emergency Room. D aratumumab should be 
discontinued, no additional daratumumab should  be adminis tered to the patient,  and the patient must 
be permanently withdrawn from daratumumab treatment.  
 
Injection -related Reactions of Grade 1 or Grade 2 : 
If the investigator assesses a Grade 1 to 2 injection -related  adverse event to be related to 
daratumumab, th en administration of daratumumab should be paused. When the patient's condition is 
stable, daratumumab administration may be resumed at the investigator's discretion.  
 
If the patient experiences a Grade [ADDRESS_1090299] be permanently withdrawn from daratumumab treatment.  
 
Injection -related Reactions of Grade 3 or Higher : 
For injec tion-related reactions (other than laryngeal edema or bronchospasm) that are Grade 3, the 
daratumumab administration must be stopped, and the patient must be observed carefully until 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  17 
 resolution of the adverse event or until the intensity of the event decre ases to Grade 1, at which point 
the daratumumab administration may be restarted at the investigator’s discretion. If the intensity of the 
event returns to Grade [ADDRESS_1090300] be 
stopped, and the patient permanently discontinued from daratumumab treatment.  
  
Recurrent Injection -related Reactions : 
If a Gra de 3 injection -related reaction (or Grade 2 or higher event of laryngeal edema or a Grade 2 or 
higher event of bronchospasm) recurs during or within [ADDRESS_1090301] be permanently discontinued from d aratumumab treatment.  
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.1  ACQUISITION  AND ACCOUNTABILITY  
 
Daratumumab SC will be supplied by [CONTACT_48824], LLC through the drug distribution vendor 
CSM (Clinical Supplies Management Holdings, INC). A drug template request form will be sent to the 
central drug ordering mailbox. During the course of the study, the site will ensure drug inventory is 
checked on a regular basis and enough lead time is given to order, process, and ship drug to the site.  
 
6.2.[ADDRESS_1090302] is co -
formulated at a concentration of 120 mg/mL daratumumab  with 2000 U/mL rHuPH20 in an isotonic 
buffer consisting of histidine, sorbitol, methionine,  NaCl and polysorbate [ADDRESS_1090303] STORAGE AND STABIL ITY 
 
The daratumumab vials should be stored in the original carton in a refrigerator at 2 ˚C to 8 ˚C and  
must not be utilized after the expi[INVESTIGATOR_83379]. The product must be protected  from light 
and must not be frozen. Since daratumumab does not contain preservatives, any  unused portion 
remaining in the vial must be discarded.  
 
6.2.[ADDRESS_1090304] the expi[INVESTIGATOR_790941] . 
3. After removal of the vial from 2 -8˚C storage, equilibrate at ro om temperature (RT) for at least 30 
minutes. 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090305] not be stored at room temperature and room light for more than 24 hours cumulative 
hold (including equilibration time before first vial puncture ). 
5. The maximum time at room temperature and room ligh t from vial puncture to administration to the 
subject is 4 hours.  
6. Remove cap and clean top of vial with alcohol wipe . 
7. Gently swirl the vial (do not shake). Inspect the vial for any visible particles . Drug product  (DP)  
solution should be colorless to yellow . Do not use the solution if it contains large number of white, 
clear or translucent particles or if it contains dark opaque particles.  
8. Attach disk filter, spi[INVESTIGATOR_790942] 20 mL sterile syringe.  
9. Withdraw the entire contents o f the RT equilibrated vial through the disk filter, spi[INVESTIGATOR_790943] . 
10. If a filter becomes clogged or leaking is observed, obtain a new vial  and a new filter, and re -start the 
withdraw al process into a new syringe.  
11. Some bubbles/foaming may be o bserved upon filtration. This is normal and does not affect DP 
quality.  If multiple small bubbles/foaming are observed, let the syringe rest for 1  or 2 minutes to let 
the bubbles/foam dissipate.  If a small amount of large air bubbles is observed, gently ta p the syringe 
with your fingers until the air bubbles rise to the top of the syringe.  
12. Remove and discar d the disk filter and transfer needle, mini -spi[INVESTIGATOR_2531], or filter needle . 
13. If air bubbles were previously observed, slowly push the plunger up to force the air  bubbles out of 
the syringe.  
14. Check the volume in the syringe.  
15. Upon filtration and after removal of air, the syringe must contain at least [ADDRESS_1090306] be used for filtration of the second vial of DP into the 
same syringe (with the previously filtered DP).  
17. A winged infusion set or a syringe tip cap should be attached at this time.  
18. The winged infusion set attached can be adjusted to final dose of 15 mL at this time point. 
Alternatively (if a syringe tip cap is used), adjustment for the final dose can be accomplished in the 
patient  care area.  
 
6.2.5  ADMINISTR ATION  
 
1. Remind the patient that they should try to remain still during the procedure and to inform the 
Health Care Provider  (HCP) if they are uncomfortable . 
2. Check the label on the prepared syringe to confirm that the drug has not passe d the expi[INVESTIGATOR_790944] . 
3. Inspect the syringe for any visible particles: Drug product solution should be colorless to yellow. Do 
not use the solution if it contains large number of white, clear or  translucent particles or if it 
contains dark opaque p articles.  
4. Ensure the intended dose is available in the syringe: A) If the syringe was delivered with a syringe tip 
cap: remove the syringe tip cap and attach a winged infusion set and adjust to 15mL DP in the 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  19 
 syringe. B ) If the syringe was delivered with a  winged infusion set: remove needle cap from the 
winged infusion set and confirm that 15mL are present in the syringe.  
5. Select a site for SC injection: abdomen only, ~ 3 inch (7.5 cm) to the right or left side of the navel.  
6. Cleanse the area (~ 2 inch or 5 c m) around the site with alcohol wipe . 
7. Pi[INVESTIGATOR_820] a 2 -inch (5 cm) fold of the cleaned skin at the targeted SC injection site between the thumb 
and index finger and hold firmly . 
8. Hold the winged infusion set by [CONTACT_790966]. Insert the needle at a 45 -degree angle.  
9. Release pi[INVESTIGATOR_790945] . 
10. Hold the syringe with one hand. With the other, pull back the plunger slightly to check for blood to 
make sure that a blood vessel has not been punctured.  
11. Use one hand to push the plunger rod and another hand to ho ld the winged infusion set for stability 
during injection . 
12. Deliver  the dose by [CONTACT_790967] 3 to 5 minutes.  Try to maintain a constant 
rate during injection . 
13. Check for leakage during administration and monitor the injection site . 
14. If healthcare provider (HCP ) feels arm fatigue , delivery may be paused. If the patient is experiencing 
pain the rate of the injection may be slowed down.  
15. If the patient is experiencing pain or significant discomfort that is not alleviated by [CONTACT_790968], 
the injection a second injection site may be chosen on the opposite side of the abdomen (left or 
right of navel). Additional site preparations and needle safety precautions are required.  
16. Remove the needle from the skin. Do not flush the winged infusion set.  Do not press or rub the site 
of injection.  
17. Immediately place the syringe and needle component into a disposal container.  
 
6.3 MEASURES TO MINIMIZE  BIAS : RANDOMIZATION  AND BLINDING  
 
Not applicable . (This is an open -label study. ) 
 
6.4 STUDY INTERVENTION  COMPLIANCE  
 
Not applicable. ( All doses of the study medication wi ll be administered at the Resear ch Center.)  
 
6.5 CONCOMITANT THERAPY  
 
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed cli nician. Medications to be reported in the Case Report Form ( CRF) are 
concomitant prescription medications, over -the-counter medications and supplements . 
 
As per the inclusion criteria, i f the subject is receiving a cholinesterase inhibitor (donepezil, riva stigmine, 
or galantamine) and/or memantine, the dose must have been stable for at least [ADDRESS_1090307] within 60 days or 5 half -
lives (whichever is longer) prior to the screening visit or anti-amyloid -beta or anti -tau protein 
monoclonal antibodies within one year prior to the screening visit , and for the duration of the trial. To 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  20 
 minimize the risk of injection site hematomas, anticoagulant medications, including  warfarin , 
dabigatran, rivaroxaban, api[INVESTIGATOR_3822], edoxaban, heparin, or enoxaparin , are also prohibited throughout 
the treatment phase of the study  (through Visit 17) . Live/live -attenuated bacterial or viral vaccine s are 
prohibited  from  3 months prior to the screening visit  and throughout the treatment phase of the study 
(through Visit 17). This includes oral t yphoid , oral cholera , measles, m umps , rubella , oral polio (S abin) , 
yellow fever , varicella (Varivax or Zostavax ), rotavirus , Japanese encephalitis , or live -attenuated 
influenza (FluMist ) vaccine s. Treatment with immunosuppressive medications, such as azathioprine, 
cyclosporine, methotrexate, tacrolimus, or mycophe nylate , is prohibited from 2 months prior to the 
screening visit and throughout the treatment phase of the study (through Visit 17).  Treatment with 
courses of corticosteroids longer than 5 days are prohibited from 2 months prior to the screening visit 
and throughout the treatment phase of the study (through Visit 17).  Due to potential interaction s with 
rHuPH20  that could slow absorption of study medication, treatment with estrogens , or aspi[INVESTIGATOR_9601] a dose 
higher  than 325 mg daily , is prohibited throughout the  treatment phase of the study (through Visit 17). 
Medications that could have adverse effects on cognition, including opi[INVESTIGATOR_2467], centrally acting 
anticholinergic medications, sedative/hypnotic medications, and benzodiazepi[INVESTIGATOR_1651], are not to be used 
within 72 hours prior to cognitive testing (at Screening, Visit 11, Visit 18, and Visit 19).  
 
6.5.1  RESCUE MEDICINE  
Not applicable.  
 
7 STUDY INTERVENTION  AND PARTICIPANT  DISCONTINUATION /WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTIO N 
 
Dose Delays and Dose Modifica tions : 
Individual dose modification of daratumumab is not permitted, but dose delay is recommended as the 
primary method for managing daratumumab -related toxicities.  
 
Daratumumab -Related  Toxicity Management : 
If any of the following criteria are met and th e toxicity is more than expected daratumumab injection 
must be held to allow for recovery from toxicity. If attribution is unclear, then daratumumab should be 
held until recovery from toxicity as noted below.  
 
The criteria for a dose delay are:  
• Grade 4 h ematologic toxicity  
• Grade 3 thrombocytopenia with bleeding  
• Febrile neutropenia  
• Grade 3 or higher non -hematologic toxicities with the following exceptions:  
Grade 3 nausea that responds to antiemetic treatment within 7 days  
Grade 3 vomiting that respon ds to antiemetic treatment within 7 days  
Grade 3 diarrhea that responds to antidiarrheal treatment within 7 days  
Grade 3 fatigue that was present at baseline or that lasts for <[ADDRESS_1090308] 
administration of daratumumab  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  21 
 Grade 3 asthenia that was p resent at baseline or that lasts for <[ADDRESS_1090309] be fully recovered. If 
daratumumab administration does not commence within the prespecified window of the scheduled 
administration date (Table 3), then the dose will be considered a missed dose. Administration may 
resume at the next planned dosi ng date.  
 
Table 3:  Daratumu mab -related Toxicity Management  
Daratumumab Dosing 
Frequency  Dose Missed Dosing Resumption 
Weekly >3 days Next planned weekly dosing date 
Every 2 weeks >7 days Next planned every-2-weeks dosing date 
 
Interruption or discontinu ation from daratumumab SC  infusions does not mean discontinuation from 
the study, and subjects will be asked to return for scheduled assessments as per the protocol at Visit 11, 
Visit 18, and Visit 19, if not already completed .  If a clinically sig nificant  finding is identified (including, 
but not limited to changes from baseline) after enrollment, the investigator or quali fied designee will 
determine if any change in participant management is needed. Any new clinically relevant finding will be 
reported as an adverse event (AE) . 
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Participant s are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue  or withdraw a participa nt from  the study for the foll owing reasons : 
 
1. Significant study intervention non-compliance  
2. If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of th e 
participant  
3. If the participant meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation  
 
The reason for participant discontinuation  or withdrawal from the study will be recorded on the Case 
Report Form ( CRF).  
 
7.[ADDRESS_1090310] to follow -up if he or she fails to return for 2 scheduled visits and is 
unable to be contact[CONTACT_126457] .  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090311] be taken if a participa nt fails to return to the clinic for a required study visit:  
1. The site will attempt to contact [CONTACT_790969]/or should continue in the study.  
2. Before a participant is deemed lost to follow -up, the investigator or designee will make every effort 
to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if neces sary, a certified 
letter to the participant’s last known mailing address or local equivalent methods). These contact 
[CONTACT_13140]’s medical record or study file.  
3. Should the participant  continue to be unreachable, he or she will be considered to have withdrawn 
from the study with a primary rea son o f lost to follow -up. 
 
8 STUDY ASSESSMENTS AN D PROCEDURES  
 
8.1 EFFICACY ASSESSMENTS  
  
Alzheimer's Disease Assessment Scale -cognitive subscale (ADAS -Cog): The ADAS -Cog is the most wide ly 
used cognitive scale in AD clinical studies . The standard 11 -item version (ADAS -Cog/11) includes both 
subject -completed tests and observer -based assessments . Specific tasks include Word Recall, Naming 
Objects and Fingers, Commands, Constructional Praxis , Ideational Praxis, Orientation, Word Recognition, 
and Language . The score ranges from 0 to 70 with each point representing a performance error and 
higher  scores reflecting worse  performance  (Rosen et al. 1984). An improvement (decrease) of ≥ 4 
points in ADAS -cog/11 score has been deemed to be clinically meaningful  (Raina et al.  2008).  The 12 -
item version (ADAS -Cog/12) adds a delayed word recall task, scored from 0 to 10. The ADAS -Cog/12 
score is the total of the ADAS -Cog/11 plus the delayed recall s core, and therefore has a range of 0 to 80  
(Sano et al. 2011) . The ADAS -Cog will be administered at the Screening Visit , Visit 11, Day 85+/ -2, Visit 
18, Day 176+/ -3, and Visit 19, Day 246+/ -7. 
 
Clinical Dementia Rating Scale Sum of Boxes (CDR -SB): The CDR is a c linical global rating scale requiring 
the interviewing of both the  subject and a study partner who knows and has contact [CONTACT_1155]. 
The CDR is a  clinician -directed assessment of both cognition and function, and is intended to capture the  
state and t herefore the disease stage of the individual  (Hughes et al . 1982).  The CDR -SB has been 
proposed as an  acceptable approach for following disease progression and confirming treatment in AD  
(Lynch et al. 2006) . The CDR assesses [ADDRESS_1090312] function: memory, orientation, judgment and  
problem solving, community affairs, home and hobbies and personal care. Each of these  items has a 
maximum possible score of 3 points and the total score is a sum of the item  scores (sum of boxes) giving 
a total possible sc ore of [ADDRESS_1090313] will be 
administered at the Screening Visit, Visit 11, Day 85+/ -2, Visit 18, Day 176+/ -3, and Visit 19, Day 246+/ -7. 
 
Mini Mental State Examination (MMSE ): The MMSE is a  30-point scale that measures orientation to 
time and place, registration, immediate  and delayed recall, attention, language, and drawing  (Folstein et 
al. 1975) . Scores range from 0 (most impaired) to  30 (no impairment).  The MMSE will be  administered at 
the Screening V isit, Visit 11, Day 85+/ -2, Visit 18, Day 176+/ -3, and Visit 19, Day 246+/ -7. 
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  23 
 AD Composite Score (ADCOMS ): The ADCOMS is a composite score derived from a weighted 
combination of selected items from the ADAS -cog/12, MMSE, and CDR -SB. The range of the ADCOMS i s 
between 0 and 1.97. A higher score is indicative of greater impairment. Items contributing  to the 
ADCOMS include 4 items of the ADAS -cog, two items of the MMSE  (scored  in reverse , as item maximum 
score minus measured score) , and all six items of the CDR -SB (Wang et al. 2016) . 
 
8.2 SAFETY AND OTHER ASSESSMENTS  
 
Demographics:  Subject demographic  information will be collected at the Screening Visit, including  date 
of birth (or age), sex, race/ethnicity, native language, and highest education level.  
 
Medical h istory: Medical and surgical history, prior and concurrent medications including cholinesterase 
inhibitor and memantine use, and current medical conditions will be recorded at the Screening Visit.  
Medical history will include history of cognitive  impairment  and psychiatr ic history . 
 
Height and weight: Height will be measured at the Screening Visit. Weight will be measured at every 
visit except Visit 11 (the interim cognitive testing visit).  
 
Vital signs: Temperature, blood pressure, heart rate, and respi[INVESTIGATOR_790946] V isit, prior to every infusion , [ADDRESS_1090314] infusion (Visit 1), 1 hour after 
every subsequent infusion (Visits 2 through 10 and 12  through 17) , and at Visits 11, 18, and 19 . 
 
Physical and neuro logical examination: Physical and neurological examination  will be performed by a 
study physician at the Screening Visit, Visit 11, Visit 18, and Visit 19.  
 
Modified Hachinski Ischemia Score (MHIS) : The Rosen -Modified Hachinski Ischemia Score (MHIS)  is a 
tool to identify the possibility of a vascular etiology for a subject’s  cognitive impairment  (Rosen et al. 
1980) . It will be performed by a study physician at the Screening Visit.  
 
Geriatric Depression Scale  (GDS): The Geriatric Depression  Scale (GDS) (15 p oint version) is a  
screening assessment tool for depression specifically  designed for older people (Sheikh and Yesavage 
1986 ). A score of 5 or higher is suggestive of depression.  It will be performed at the Screening Visit.  
 
Electrocardiogram (ECG): 12-lead ECG will be obtained for screening purposes only at the Screening 
Visit.  
 
Blood tests: Blood tests  to be  collected at the Screening V isit will include complete blood count (CBC), 
comprehensive metabolic panel  (CMP) , prothrombin time ( PT)/international no rmalized ratio ( INR), 
activated partial thromboplastin time ( APTT ), thyroid -stimulating hormone ( TSH), vitamin B12 level , 
hepatitis B surface antigen ( HBsAg ), hepatitis B core antibody ( HBcAb ), hepatitis C virus antibody 
(HCVAb), and human immunodeficiency  virus antigen/antibody screen (HIVAg/Ab) . Blood samples will 
be obtained at Visit 1, prior to the first infusion, for type and screen and flow cytometry. After the first 
dose, subjects will have a CBC performed within 48 hours prior to each subsequent  infusion (Visits 2 
through 10 and 12 through 17). Additional safety laboratory monitoring will include a CMP every 4 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  24 
 weeks  (Visits 4, 8, 10, 13, 15, and 17). CBC and CMP  will also be obtained 12 weeks  after the final dose 
(Visit 19).  
 
Brain MRI:  Brain MRI wil l be performed within the screening period and at Visit 18. MRI acquisition will 
be performed on a 3T MRI scanner (Siemens MAGNETOM Prisma). The sequences obtained will include 
proton magnetic resonance spectroscopy (1H-MRS) from a mid -sagittal oblique 10. 8 cm3 (2 × 2 × 2.7 cm) 
voxel in the region of the precuneus and posterior cingulate cortex.  
 
Amyloid PET scan of brain: An amyloid PET scan may be performed within the  screening period to 
confirm deposition of amyloid in  the brain. A historical amyloid pos itive PET scan may be used provided 
that the scan and result are  considered acceptable by [CONTACT_11168].  
 
Concomitant medications:  Concomitant medications  will be recorded at the Screening Visit and 
reviewed and updated at Visits 1 -19. 
 
Adverse events r eview:  Subjects and study partners will be asked about adverse events at Visits [ADDRESS_1090315] or study partner, in person or by [CONTACT_756].  
   
8.3 ADVERSE EVENTS  AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERS E EVENTS  (AE)  
 
An adverse event is any untoward medical occurrence in a clinical study subject administered a 
medicinal (investigational or non -investigational) product. An adverse event does not necessarily  have a 
causal relationship with the treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational or non - investigat ional) product, whether or not related to that 
medicinal (investigational or non -investigational) product. [Definition per International Conference on 
Harmonisation (ICH) ] 
 
This includes any occurrence that is new in onset or aggravated in severity or freq uency from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities  
 
8.3.2  DEFINITION OF SERIOU S ADVERSE EVENTS  (SAE)  
 
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal  Products 
for Human Use is any untoward medical occurrence that at any dose:  
 
• Results in death  
• Is life -threatening  (The subject was at risk of death at the time of the event. It does not refer to 
an event that hypothetically might have caused death if it were more severe.) * 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability/incapacity  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  25 
 • Is a congenital anomaly/birth defect  
• Is a suspected transmission of any infectious agen t via a medicinal product  
• Is medically important* * 
 
*Life-Threatening Conditions:  
Disease progression should not be recorded as an adverse event or serious adverse event term; instead, 
signs and symptoms of clinical sequelae resulting from disease progr ession/lack of efficacy will be 
reported if they fulfill the serious adverse event de finition . 
 
**Medical and scientific judgment should be exercised in deciding whether expedited reporting is also 
appropriate in other situations, such as important medical  events that may not be immediately life 
threatening or result in death or hospi[INVESTIGATOR_46822]. These should usually 
be considered se rious.  NOTE: DEATH FOR ANY REASON SHOULD BE REPORTED AS A SERIOUS ADVERSE 
EVENT.  
[IP_ADDRESS]  HOSPI[INVESTIGATOR_790947], it is the sign, symptom or diagnosis which led to the hospi[INVESTIGATOR_790948].  
 
Any event requiring hospi[INVESTIGATOR_790949] a serious adverse event, except hospi[INVESTIGATOR_23741]:  
 
• Hospi[INVESTIGATOR_790950] (e.g., social reasons such 
as pending placement in long -term care facility)  
• Surgery or procedure planned before entry into the study. [Note: Hospi[INVESTIGATOR_790951]. 
Any adverse event that results in a prolongation of the originally planned hospi[INVESTIGATOR_312202] a new serious adverse event.]  
 
 
 
8.3.3  CLASSIFICATION OF AN  ADVERSE E VENT  
[IP_ADDRESS]  SEVERITY OF EVENT  
 
For adverse events ( AEs) not included in the protocol defined grading system, the following guidelines 
will be used to describe severi ty.  
 
• Mild  – Events require minimal or no treatment and do not in terfere with the participant ’s daily 
activities.  [Equivalent to National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Grade 1]  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  26 
 • Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measure s. Moderate events may cause some interference with functioning.  [Equivalent to NCI 
CTCAE Grade 2]  
• Severe  – Events interrupt a participant ’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentiall y life -threatening or 
incapacitating.  [Equivalent to NCI CTCAE Grade 3 or higher] Of note, the term  “severe” does not 
necessarily equate to “serious”.  
 
[IP_ADDRESS]  RELATIONSHIP TO STUD Y INTERVENTION  
 
All adverse events ( AEs) must have their relationship to study inter vention  assessed  by [CONTACT_237357]/her clinical judgment. 
The degree of certainty about causality will be graded using the categories below. In a clinical trial, the 
study pro duct must always be suspect.  
 
• Related  – The AE is known to occur with the study intervention , there is a reasonable possibility 
that the study intervention  caused the AE, or there is a temporal relationship between the study 
intervention  and event. Reason able possibility means that there is evidence to suggest a causal 
relationship between the study intervention  and the AE. 
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention  caused the event, there is no te mporal relationship between the study intervention  
and event onset , or an alternate etiology has been established.  
 
[IP_ADDRESS]  EXPECTEDNESS  
 
The investigator  will be responsible for determining whether an adverse event ( AE) is expected or 
unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the event is 
not consistent with the risk information previously described for the study intervention . 
 
An adverse event is considered unlisted if the nature or severity is not consistent with the applicable 
product reference safety information. For a medicinal product(s) with a marketing authorization, the 
expectedness of an adverse event will be determined by [CONTACT_423143].  
 
http://www.darza lex.com/shared/product/darzalex/darzalex -prescribing -information.pdf  
 
For daratumumab, the expectedness of an adverse event will be determined by [CONTACT_350955]'s Brochure . 
8.3.4  TIME PERIOD AND FREQ UENCY FOR EVENT ASSE SSMENT AND  FOLLOW -UP 
 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the attention of 
study personnel during study visits and interviews of a study participant  presenting for medical care, or 
upon review by a study monitor.  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  27 
  
All A Es including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate  case report form  (CRF). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by [CONTACT_21218] a diagnosis), and time of resolution/stabilization of the event. All AEs 
occurring while on study must be documented appropriately regardless of relationship. All AEs will be 
followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant  is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition  deteriorates at any 
time during the  study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity  to be performed. A Es characterized as intermittent require documentation of 
onset and duration of each epi[INVESTIGATOR_1865].  
 
The investigator or study coordinator  will record all reportable events with start dates occurring any 
time after informed consent is obtained until 7 (for nonserious AEs) or 30 days (for SAEs) after the last 
day of study partici pation.  At each study visit, the study staff  will inquire about the occurrence of 
AE/SAEs since the last visit.  Events will be followed for outcome information until resolution or 
stabilization.  
 
All serious adverse events that have not resolved by [CONTACT_941] e nd of the study, or that have not resolved 
upon discontinuation of the subject's participation in the study, must be followed until any of the 
following occurs:  
•  The event resolves  
•  The event stabilizes  
•  The event returns to baseline, if a baseline v alue/status is available  
•  The event can be attributed to agents other than the study drug o r to factors unrelated to study  
conduct  
•  It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to pro vide additional information, lost to follow -up after demonstration of due 
diligence with follow -up efforts)  
 
Maintenance of Safety Information : 
All safety data should be maintained in a clinical database in a retrievable format. The P rincipal  
Investigator  shall provide all adverse events, both serious and non -serious, in report format. However, in 
certain circumstances more frequent provision of safety data may be necessary, e.g. to fulfill a 
regulatory request, and as such the data shall be made available within a reasonable timeframe at 
Janssen Scientific Affairs, LLC request.  
 
8.3.5  ADVERSE EVENT REPORT ING  
 
All adverse events (AEs) will be recorded in the Case Report Form (CRF), and will be reviewed on an 
ongoing basis by [CONTACT_790970].  The Principal Investigator [INVESTIGATOR_790952] -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090316] quality complaints (PQCs), and 
special situations including pregnancies . The P rincipal  Investigator  will provide safety information to 
Janssen Scientific Affairs, LLC on adverse events, special situations including pregnancies and product 
quality complaints as defined within this section.  This s tudy has been designated as an interventional 
study.  As such, all adverse events for Janssen Medicinal Products regardless of causality and speci al 
situations excluding those from subjects not exposed to a Janssen Medicinal Product and product quality 
complaints with or without an adverse event as described in this Exhibit will be reported from the time a 
subject has signed and dated an Informed Co nsent Form (ICF) until completion of the subject’s last 
study -related procedure (which may include contact [CONTACT_20687] -up safety).  Serious adverse events will 
be reported for [ADDRESS_1090317] under study in a form provided by [CONTACT_48824], LLC 
in ac cordance with the Transmission Methods  described below , in English within 24 -hours of becoming 
aware of the event(s).  
 
Transmission Methods : 
The following methods are acceptable for transmission of safety information to Janssen Scientific 
Affairs, LLC:  
•  Electronically via Janssen SECURE Email service (preferred)  
•  For business continuity purposes, if SECURE Email is non -functional:  
-  Facsimile (fax), receipt of which is evidenced in a successful fax transmission report  
-  Telephone (if fax is non -functi onal).  
 
Please use the contact [CONTACT_83412], LLC.  
 
Dissemination of Safety Information from Janssen to Institution/Principal Investigator : 
[INVESTIGATOR_790953]’s IRB in accordance with Fede ral regulations [ADDRESS_1090318] Study visit according to the Protocol (i.e. Last Subject Last Visit has occurred).  
 
For SAEs, special reporting situations and PQCs following exposure to a non -Jans sen medicinal product 
under study, the Principal Investigator [INVESTIGATOR_83391]/competent authority or 
the manufacturer of that medicinal product (in the absence of appropriate local legislation) as soon as 
possible.  
 
8.3.6  SERIOUS ADVERSE  EVENT REPORTING  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  29 
  
The study clinician will immediately report to Janssen Scientific Affairs, LLC  any serious adverse event, 
whether or not considered study intervention  related, including those listed in the protocol or 
Investigator ’s Brochure and must in clude an assessment of whether there is a reasonable possibility that 
the study intervention  caused the event.  
 
All serious adverse events ( SAEs ) will be followed until satisfactory resolution or until the investigator 
deems the event to be chronic or the  participant is stable. Other supporting documentation of the event 
may be requested by [CONTACT_48824], LLC  and should be provided as soon as possible.  
 
The Institution/Principal Investigator  [INVESTIGATOR_790954] 
(FDA) of any unexpected fatal or life -threatening suspected adverse reaction as soon as possible , but in 
no case later than 7 calendar days after the Institution/Principal Investigator ’s initial receipt of the 
information.   In addition, the Institution/Principal Investigator  [INVESTIGATOR_790955] ( IND) safety report of potential serious risks, from clinical trials or any other source, as soon as 
possible, but in no case later than 15 calendar days after the Instit ution/Principal Investigator  
[INVESTIGATOR_316231] . 
 
8.3.[ADDRESS_1090319]’s treating physician(s). A 
summary of the aggregate results of the study will be provided to study par ticipants after data analysis 
is complete, and will be posted on the ClinicalTrials.gov  website.  
 
8.3.[ADDRESS_1090320] are events that Janssen Scientific Affairs, LLC is actively monitoring as 
a result of a previo usly identified signal (even if nonserious). These adverse events are:  
 
• Infusion reactions: ≥ Grade 3  
• Infections: ≥ Grade 4  
• Cytopenias: ≥ Grade 4  
• Tumor lysis syndrome  
• Other malignancies  
• Intravascular hemolysis – all Grades  
 
Any Adverse Event of Special Interest that is to be reported to Janssen Scientific Affairs, LLC should be 
recorded on a Serious Adverse Event Report Form and be reported to Janssen Scientific Affairs, LLC 
within [ADDRESS_1090321] that require expediting reporting and/or safety 
evaluation include, but are not limited to:  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  30 
  
•  Drug exposure during pregnancy (maternal and paternal)  
•  Overdose of a Janssen medicinal product  
•  Exposure to a Janssen med icinal product from breastfeeding  
•  Suspected abuse/misuse of a Janssen medicinal product  
•  Inadvertent or accidental exposure to a Janssen medicinal product  
•  Any failure of expected pharmacological action (i.e., lack of effect) of a Janssen medicina l product  
•  Medication error involving a Janssen medicinal product (with or without patient exposure to the 
Janssen medicinal product, e.g., name [CONTACT_2976])  
•  Suspected transmission of any infectious agent via administration of a medicinal product  
•  Unexpected therapeutic or clinical benefit from use of a Janssen medicinal product  
 
These safety events may not meet the definition of an adverse event; however, from a Janssen Scientific 
Affairs, LLC perspective, they are treated in the same manner as advers e events. Special situations 
should be recorded on the Adverse Event page of the CRF.  
 
Any special situation that meets the criteria of a serious adverse event should be recorded on a Serious 
Adverse Event Report Form and be reported to Janssen Scientific Affairs, LLC within [ADDRESS_1090322] be reported to Janssen Scientific Affairs, LLC by [CONTACT_9532]  [INVESTIGATOR_874] 24 hours of becoming aware of the event using t he Serious Adverse Event Form. 
Abnormal pregnancy outcomes (e.g. spontaneous abortion, fetal death, stillbirth, congenital anomaly, 
ectopic pregnancy) are considered serious adverse events and must be reported using the Serious 
Adverse Event Form.  
 
Any su bject who becomes pregnant during the study must be promptly withdrawn from the study and 
discontinue further study treatment.  
 
Because the effect of the Janssen medicinal product on sperm is unknown, pregnancies in partners of 
male subjects exposed to a J anssen medicinal product will be reported by [CONTACT_079] 
[INVESTIGATOR_874] [ADDRESS_1090323] QUALITY COMP LAINT S (PQC)  
 
A product quality complaint  is defined as any suspi[INVESTIGATOR_1884] a product defect related to a potential quality  
issue during manufacturing, packaging, release testing, stability monitoring, dose preparation, storage 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090324].  Lot and batch 
numbers are of high significance and need to be col lected whenever available.  
 
Examples of PQC include but are not limited to:  
 
• Functional Problem: e.g., altered delivery rate in a controlled release product  
• Physical Defect:  e.g. abnormal odor, broken or crushed tablets/capsules  
• Potential Do sing Dev ice Malfunction: e.g., autoinjector button not working, needle detaching 
from syringe  
• Suspected Contamination  
• Suspected Counterfeit  
 
A PQC may have an impact on the safety and efficacy of the product. Timely, accurate, and complete 
reporting and analys is of PQC information from studies are crucial for the protection of patients, 
investigators, and Janssen Scientific Affairs, LLC, and are mandated by [CONTACT_67819]. 
Janssen Scientific Affairs, LLC has established procedures in conformity w ith regulatory requirements 
worldwide to ensure appropriate reporting of PQC information. Lot and/or Batch #s shall be collected or 
any reports failure of expected pharmacological action (i.e., lack of effect). The product should be 
quarantined immediately  and if possible, take a pi[INVESTIGATOR_1103].  
 
All initial PQCs involving a Janssen medicinal product under study must be reported to Janssen Scientific 
Affairs, LLC by [CONTACT_079]  [INVESTIGATOR_874] [ADDRESS_1090325]  will provide additional information/form to be completed.  
 
If the defect for a Janssen medicinal product under study is combined with either a serious adverse 
event or nonserious adverse event, the Principal Investigator  [INVESTIGATOR_790956], LLC according to the serious adverse event reporting timelines.  A sample of the suspected 
product should be maintained for further investigation if requested by [CONTACT_48824], LLC.  
 
8.4 UNANTICIPATED PROBLE MS 
 
8.4.1  DEFINITION OF U NANT ICIPATED PROBLEMS (UP)  
 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
participant s or others to include, in general, any incident, experience, or outcome that meets all of the 
following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)-
approved research protocol and informed consent document; and (b) the cha racteristics of the 
participant  population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_217868]); and  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  32 
 • Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
8.4.2   UNANTICIPATED PROBLE M REPORTING  
 
The investigator  will report unanticipated problems ( UPs) to the reviewing Institutional Review Board 
(IRB). The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project  
number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of any changes to the protocol or other correctiv e actions that have been taken or 
are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
 
• UPs that are serious adverse events ( SAEs) will be reported to the IRB and to the Independent 
Safety Monitor as soon as possible , but within 5 business days  of the investigator becoming 
aware of the event.  
• Any other UP will be reported to the IRB and to the Independent Safety Monitor as soon as 
possible, but within 5 business days  of the investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s 
written reporting procedures) and the Office of the Human Research Protections ( OHRP). The 
OHR P Director ensu res that all steps of this process  are completed within [ADDRESS_1090326] their willingness to continue participation in the study. If the UP requires mo dification of the 
informed consent form, active subjects will be re -consented.  
 
9 STATISTICAL CONSIDER ATIONS   
 
9.1 STATISTICAL HYPOTHES ES 
SPECIFIC AIM: To estimate the proportion of patients with Alzheimer’s disease who respond to 
daratumumab.  
 
OUTCOME VARIABLE:  A patient will be considered a responder if they improve by a minimum of 4 points 
on the ADAS -cog/11 from baseline at 25 weeks . 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  33 
  
STATISTICAL METHODS: The proportion of patients who respond to daratumumab will be estimated, 
and the associated 95% exact bin omial confidence interval will be calculated.  
 
 Primary Efficacy Endpoint:  
 
- Responder rate defined as improvement in standard 11 -item Alzheimer's Disease Assessment Scale -
cognitive subscale (ADAS -cog/11) score of ≥ 4 points at 25 weeks  compared with base line 
 
 Secondary Efficacy Endpoints:  
 
- The proportion of subjects who are unchanged or improved from  baseline at 25 weeks  in ADAS -cog/12 
score (standard [ADDRESS_1090327] recall)  
 
- The proportion of subjects who are unchanged or improved from  baseline at 25 weeks  in Mini Mental 
State Examination (MMSE) score  
 
- The proportion of subjects who are unchanged or improved from  baseline at 25 weeks  in Clinical 
Dementia Rating Scale Sum of Boxes (CDR -SB) score  
 
- The proportion of subjects who are unchan ged or improved  from baseline at 25 weeks  in ADCOMS 
score (a composite score derived from a weighted combination of selected items from the ADAS -cog/12, 
MMSE, and CDR -SB) 
 
 
 Secondary Safety  Endpoints:  
 
- The proportion of subjects with one or more treatmen t-emergent adverse events  
 
- The proportion of patients with one or more treatment -emergent serious adverse events  
 
 Tertiar y/Exploratory Endpoints : 
 
- Pattern of change over time at baseline  (prior to the start of daratumumab  treatment ), 12 weeks  
(midpoint ), 25 weeks  (endpoint), and 36 weeks  (12 weeks  after completion of treatment ) in the 
following cognitive ou tcome measures : ADAS -cog/11 , ADAS -cog/[ADDRESS_1090328]-SB, ADCOMS  
 
- Change from baseline at 25 weeks  in CD38 expression on circulating (whole blood) CD 8+ T -cells 
measured with flow cytometry  
 
- Change from baseline at 25 weeks  in metabolite ratios : N-acetylaspartate/creatine  (NAA/Cr) , myo -
inositol/creatine  (mI/Cr) , choline/creatine  (Cho/Cr) , and N -acetylaspartate/myo -inositol  (NAA/mI)  on 
single -voxel pro tein magnetic resonance spectroscopy from the precuneus and posterior cingulate 
region  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  34 
 9.2 SAMPLE SIZE  DETERMINATION  
 
This is a pi[INVESTIGATOR_799], the purpose of which is explore whether there is a clinically meaningful  efficacy 
signal for daratumumab in patients w ith mild to moderate Alzheimer's disease. The proposed sample 
size of 15 patients is based on feasibility and availability of resources, and not on a formal power 
calculation.  
 
The following table provides estimates of proportions and their associated 95% confidence intervals for 
a sample size of 15 subjects.  
 
N=[ADDRESS_1090329] Lower 95% 
Confidence Interval  Exact Upper 95% 
Confidence Interval  
[ADDRESS_1090330] 95% binomial 
confidence interval is 0.213, (i.e., we are 95% certain that the true proportion with a response is no 
lower than 0.213).  Based on p revious results in patients with mild to moderate AD maintained on stable 
treatment with a cholinesterase inhibitor, the expected responder rate at 25 weeks  (defined as 
improvement in ADAS -cog/11 sco re of ≥ 4 points) is 20% (0.20) (Rockwood et al. 2007). Therefore, if [ADDRESS_1090331] one dose of study medic ation will be included in all efficacy 
and safety analyses.  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  35 
 9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
 
Descriptive statistics (mean and standard deviation, median, minimum, and maximum) for all outcome 
measures at each timepoint will be calculated.  
 
Plots of  the data, (including spaghetti plots) will be used to visualize patterns in the data.  Additional 
post hoc exploratory analyses may be carried out.  
 
9.4.2  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN T 
 
The 11 -item Alzheimer's Disease Assessment Scale -cognitive subs cale (ADAS -cog/11) has been a 
standard cognitive outcome measure in clinical trials for patients with mild to moderate AD. Total scores 
range from 0 –70, with higher scores indicating greater cognitive impairment. The average expected 
worsening (increase) o n this scale over 6 months in this population is in the range of 2 to 3 points. A 
clinically meaningful improvement (decrease) on this scale has been deemed to be 4 or more points. 
Based on previous results in patients with mild to moderate AD maintained o n stable treatment with a 
cholinesterase inhibitor, the expected responder rate at 25 weeks  (defined as improvement in ADAS -
cog/11 sco re of ≥ 4 points) is 20% (0.20) (Rockwood et al. 2007).  
 
A patient will be considered a responder if they improve by a min imum of 4 points on the ADAS -cog/11 
scale at 25 weeks  compared to baseline.  The proportion of patients who respond to daratumumab will 
be estimated, and the associated 95% exact binomial confidence interval will be calculated.  
 
9.4.[ADDRESS_1090332] of the proportion of subjects who are unchanged or improved 
from baseline to 25 weeks  on ADAS -cog/12 score (standard [ADDRESS_1090333] recall) , Mini 
Mental State Examination (MMSE) score , Clinical  Dementia Rating Scale Sum of Boxes (CDR -SB) score , 
and AD Composite Score (ADCOMS) .   
 
All analyses will be carried out separately for each secondary endpoint listed above.  
 
For each measure of cognitive response, a patient will be classified as stable or  improved if the score at 
25 weeks  is the same or better than at baseline.  The proportion of patients who are stable/improved, 
and the associated 95% exact binomial confidence interval will be calculated . 
 
9.4.4  SAFETY ANALYSES  
 
The proportion of patients with one or more  treatment -emergen t adverse events will be estimated, and 
the associated 95% exact binomial confidence interval will be calculated.  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  36 
 The proportion of patients with one or more treatment -emergent serious adverse events will be 
estimated, and the  associated 95% exact binomial confidence interval will be calculated.  
 
9.4.5  BASELINE DESCRIPTIVE  STATISTICS  
 
Descriptive statistics (mean and standard deviation, median, minimum, and maximum for continuous 
factors ; frequency and proportion for categorical fact ors) for demographic and clinical factors (including 
age, sex, years of education, and baseline MMSE score ) will be calculated.  
 
9.4.6  PLANNED INTERIM ANAL YSES  
 
Not applicable.  
 
9.4.7  SUB -GROUP ANALYSES  
 
Not applicable.  
 
9.4.8  TABULATION OF INDIVI DUAL PARTICIPANT  DATA  
 
Not applicable.  
 
9.4.9  TERTIARY/ EXPLORATORY ANALYSES  
 
The pattern of cognitive response to daratumumab , as measured by [CONTACT_33341] -cog/11, ADAS -cog/12, MMSE, 
CDR -SB, and ADCOMS , will be examined over time at baseline ( prior to the start of daratumumab  
treatment ), 12 weeks  (midpoint), 25 weeks  (endpoint), and 36 weeks  (12 weeks  after completion of 
treatment).  
 
For each measure of cognitive response, repeated measures analysis of variance (RMANOVA) where 
time (baseline, 12 weeks , 25 weeks , 36 weeks ) is the within subjects ef fect, and there is not between 
subjects effect, will be used to examine the changes in each outcome over time.   
 
CD38 expression in circulating CD8+ T -cells will be measured with flow cytometry  at baseline and at [ADDRESS_1090334] will be used t o examine whether there is a change at 25 weeks  vs baseline . 
 
Cerebral metaboli te ratios will be measured on single -voxel protein magnetic resonance spectroscopy 
from the precuneus and posterior cingulate region  at baseline and at 25 weeks , including:  
 
•  N-acetylaspartate/creatine  (NAA/Cr)  
•  myo-inositol/creatine  (mI/Cr)  
•  choline/creatine  (Cho/mI)  
•  N-acetylaspartate/myo -inositol  (NAA/mI)  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090335] wil l be used to examine whether there is a change at 25 weeks  vs baseline for each factor listed 
above . 
 
If the usual assumptions of the proposed parametric models are not met, an appropriate transformation 
or a suitable non -parametric method will be used.   
 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS  
 
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PRO CESS  
 
[IP_ADDRESS]  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS PROVIDED TO  
PARTICIPANTS  
 
Consent forms describing in detail the s tudy intervention , study procedures, and risks are given to the 
the subject, their study partner, and the subject's legally authorized representative (if applicable) , and 
written documentation of informed consent is required prior to starting any study -related  procedure .   
 
The following consent materials are submitted with this protocol : 
 
- Subject Informed Consent Form  
- Study Partner Information and Consent Form  
 
[IP_ADDRESS]  CONSENT PROCEDURES A ND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation.  Potential participants will be 
provided with a copy of the informed consent  document ahead of research participation. This will allow 
the subject  and their legally authorized representative (if applicable)  the necessary time to carefully 
review detailed information about the study  procedures, risks , and benefits, and ask questions or 
express concerns prior to  making a decision about  whethe r to participate.  Prior to the initiation of any 
screening or study -specific procedures, the investigator or  his  representative will explain the nature of 
the study to the subject, their study  partner, and the subject's legally authorized representative ( if 
applicable), and answer all questions regarding  this study. Participant s will be informed that 
participation is voluntary and that they may withdraw from the study at any time, without prejudice.  
The rights and welfare of the participant s will be protec ted by [CONTACT_114813].  Due to the 
inherent nature of the study population, with cognitive impairment due to Alzheimer’s disease, it is 
anticipated that many of these subjects will lack decisional capacity to provide informed consent. 
Accordingly, all potential subjects will be assessed for capacity to provide informed consent by [CONTACT_790971], who are either neurologists or g eriatric psychiatrists with extensive experience in 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090336]  or their legally authorized representative (if 
applicable) , the  person who administered the informe d consent, and any other signatories according to  
local requirements. A  separate  informed consent will also be reviewed, signed , and dated by [CONTACT_1560]'s study partner prior to beginning any study related screening  activities. A copy of each informed 
consent will be given to the subject and their study  partner and each original will be placed in the 
subject's study chart . An entry must  also be made in the subject's dated source documents to confirm 
that informed consent  was obtained prior to any study -related procedures and that the subject and 
study partner received signed  copi[INVESTIGATOR_014].  
10.1.2  STUDY DISCONTINUATIO N AND CLOSURE  
  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documentin g the reason for study suspension or termination, will be 
provided by [CONTACT_21224], investigator, funding agency, the 
Investigational New Drug ( IND) sponsor , and regulatory authorities.  If the study is prematur ely 
terminated or suspended, the  Principal Investigator ( PI) will promptly inform study participants, the 
Instituti onal Review Board ( IRB), and Janssen Scientific Affairs, LLC , and will provide the reason(s) for the 
termination or suspension.  Study partic ipants will be contact[INVESTIGATOR_530], as applicable, and be informed of 
changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
 Determination of unexpected, significant, or unacceptable risk to parti cipants  
 Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]    
 Insufficient compliance with  protocol requirements  
 Data that are not sufficiently complete and/or evaluable  
 Determination that  the primary endpoint has been met  
 Determination of futility  
 
The study may resume once concerns about safety, protocol compliance, and data quality are 
addressed , and satisfy Janssen Scientific Affairs, LLC,  the IRB, and/or the Food and Drug Administration 
(FDA). 
 
10.1.[ADDRESS_1090337] or their legally  
authorized representative .  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090338] ( IRB), regulatory agenci es, or the pharmaceutical company supplying study 
product may inspect all documents and records required to be maintained by [CONTACT_093], including 
but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the particip ants 
in this study. The clinical study site will permit access to such records.  
 
The study participant’s contact [CONTACT_252063]. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by [CONTACT_54232], Institutional policies, or regulatory requirements . 
 
The study data entry and study management systems used by [CONTACT_790972]. The Feinstein Institute for Medical Research will be used as a central location 
for data processing and management. Vanderbilt University, with collaboration from a consortium of 
institutional partners, has developed a software toolset and workf low methodology for electronic 
collection and management of research and clinical trial data. REDCap (Research Electronic Data 
Capture) data collection projects rely on a thorough study -specific data dictionary defined in an iterative 
self-documenting proc ess by [CONTACT_790973]. The interactive development and 
testing process results in a well -planned data collection strategy for individual studies.  REDCap servers 
are housed in a local data center at the Feinstein and all web -based information transmission is 
encrypted. REDCap was developed specifically around HIPAA -Security guidelines and is recommended to 
Northwell Health’s researchers by [CONTACT_717997], Research Compliance Office and 
Institutional Review Board. REDCap has been disseminated for use locally at other institutions and 
currently supports more than 2500 active institutional partners and other institutions in more than 100 
countries (www.projectredcap.org). De -identified research data may be stored on portable electronic 
devices (e.g. laptops, tablets, flash drives, etc.).  All such devices will be encrypted as per Northwell 
Health policy ( www.projectredcap.org ). 
 
Certificate of Confidentiality:  
To further protect the privacy of study participant s, a Certificate of Confidentiality  (CoC)  will be issued 
by [CONTACT_7681] ( NIH).  This certificate protects i dentifiable research information 
from forced disclosure. It allows the investigator and others who have access to research records to 
refuse to disclose identifying information on research participation in any civil, criminal, administrative, 
legislative, or other proceeding, whether at the federal, state, or local level. By [CONTACT_790974] s, 
Certificates of Confidentiality help achieve the research  objectives and promote participation in studies 
by [CONTACT_4205][INVESTIGATOR_411621].  
 
10.1.4  FUTURE USE OF STORED  SPECIMENS  AND DATA   
 
Data collected for this study will be analyzed and stored at the Feinstein Institute for Medical Rese arch .  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090339]  
Lake Succe ss, NY [ZIP_CODE]  
(516) 562 -3492  ([PHONE_16464]  (516) 734 -3532  
[EMAIL_15055]  ORC @northwell.edu  [EMAIL_15056]  
 
10.1.6  SAFETY OVERSIGHT  
 
Safety oversight will be under the direction of an Independent Safety Monitor (ISM) , a physician with 
relevant  expertise whose primary responsibility is to provide independent safety monitoring in a timely 
fashion. This is accomplished by [CONTACT_547154], immediately after they occur or are reported, 
with follow -up through resolution. The ISM will  be noti fied of SAEs  by [CONTACT_126786] 24 hours of 
knowledge of the event .  The ISM will  be notified of unexpected problems  as soon as possible, but 
within 5 business days of knowledge of the event . The ISM will  be notified within 15 business days of 
severe  (NCI CTCAE Grade 3 or 4) nonserious AEs. The study team will  report aggregate mild to moderate 
(NCI CTCAE Grade 1 or 2) nonserious AEs to the ISM  at 4-month intervals.  The ISM evaluates individual 
and cumulative participant data when making recommendation s regarding the safe continuation of the 
study.  The ISM will be independent from the study conduct and free of conflict of interest, or measures 
should be in place to minimize perceived conflict of interest.  
 
10.1.[ADDRESS_1090340] of 
the trial is in compliance with the currently approved protocol/amendment (s), with International 
Conference on Harmonisation Good Clinical Practice ( ICH GCP), and with applicable regulatory 
requirement(s).  
 
The Clinical Monitor , or designee , will perform the following oversight and monitoring tasks in 
accordance with protocol specific requirements, Good Clinical Practice Guidelines, and Northwell Health 
Policy GR080, “Human Subject Rese arch Oversight and Monitoring”.    
 
These tasks will include, but are not limited to:  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090341] review will 
be completed prior to study initiation.  All reviews will include:  
•  Study form 1572  
•  All study staff CVs and any relevant medical licenses  
•  Staff training documentation  
•  Site delegation of responsibil ity log  
•  Subject enrollment log  
•  IRB communications and approvals  
•  Current and prior protocol versions  
•  Current and prior consent forms  
•  Laboratory certifications and reference ranges  
 
2. Review of the informed consent process and documentation f or each subject (100%) who 
consents to participate in the study within [ADDRESS_1090342] source documentation with inclusion/exclusion criteria (100%).  
 
4. Review of all visit specific case report forms (100%) and partial con gruence check with electronic 
data entry on a monthly basis (two randomly selected documents per participant visit).  
 
5.        Review of all minor protocol deviations and documentation on a monthly basis (100%).  
 
6. Review and reporting of all (100%) internal ser ious adverse events or major protocol deviations 
within [ADDRESS_1090343], data and biological 
specimen  collection, documentation and completion.   
 
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run o n the database will be generated. Any missing data or data anomalies will be 
communicated to the study staff  for clarification/resolution.  
 
Quality assurance (QA) will be assessed and documented through the clinical monitoring plan detailed in 
Section 10.1 .7 above .  In addition, quality will be ensured by [CONTACT_790975]:  
 
1. Biological specimens collected for this protocol will be handled and processed according to 
Northwell Health Laboratory Science Specimen Collection and Han dling Guidelines.  Monitoring 
of clinical case report forms will include analysis of compliance with specimen collection and 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  42 
 consistency of the quality of results.  All calibration and quality assurance of laboratory testing 
equipment is routinely performe d by [CONTACT_790976].  
 
2. All medical equipment used in the care of research subjects, including but not limited to, blood 
pressure cuff, thermometer, electrocardiogram, pulse oximeter, etc. are routinely checked by 
[CONTACT_84392]’s bioeng ineering group and labeled with safety stickers at 6 -month intervals.  
 
3. Disposable patient supplies; blood collection tubes, phlebotomy supplies, syringes, etc. are 
routinel y checked for expi[INVESTIGATOR_790957] a monthly basis . 
 
4. Custom training plans will  be created for nurses that will administer study medication.  
Documentation of successful completion of training will be required before study  nurses will be 
authorized  to administer study medication.  
 
5. Investigational pharmacy records will be reviewed biannually, or more often as needed, to 
include receipt of investigational drug, storage records , temperature logs, and dispensing logs.  
 
The Clinical M onitor will verify that the clinical trial is conducted and data are generated  and biological 
specimens are collected , documented (recorded), and reported in compliance with the protocol, 
International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory 
requirements [e.g., Good Laboratory Practices ( GLP), Good Manufacturin g Practices ( GMP )].  
 
The investigational site will provide direct access to all source data/documents, and reports for the 
purpose s of monitoring and inspection by [CONTACT_9177].  
 
 
10.1.[ADDRESS_1090344]  KEEPI[INVESTIGATOR_1645]   
 
[IP_ADDRESS]  DATA COLLECTION AND  MANAGEMENT RESPONSIB ILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
investigator . The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported . 
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation 
of data.   
 
Hardc opi[INVESTIGATOR_790958] e ach participant  enrolled in the study.  Data re cord ed in the electronic case report 
form ( eCRF ) derived from source documents should be consistent with the data recorded on the source 
documents .  
 
Clinical data (including adverse events ( AEs), concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be entered into REDCap , a 21 CFR Part 11 -compliant data capture 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090345] 
protectio n and internal quality checks, such as automatic range checks, to identify data that appear 
inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source 
documents.  
 
[IP_ADDRESS]  STUDY RECORDS RETENT ION  
 
Study documents should be reta ined for a minimum of [ADDRESS_1090346] approval of a marketing application in an  International Conference on Harminosation 
(ICH) region and until there are no pending or contemplated marketing applications in an ICH region , or 
until at least [ADDRESS_1090347] elapsed since the formal discontinuation of clinical development of the study 
intervention , whichever is longer . No records will be destroyed without the written consent of Janssen 
Scientific Affairs, LLC .  
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonisation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP) requirements. The 
noncompliance may be either on th e part of the participant , the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 
These practices are consistent with ICH GCP:  
• 4.[ADDRESS_1090348] ions 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
It is the responsibility of the investigator to use continuous vigilance to identify and report protocol 
deviations . Major protocol deviations (those that affect subject safety, rights, welfare or data integrity ) 
must be reported to the IRB within ten (10) working days of discovery . Minor protocol deviations (those 
that do not affect subject safety, rights, welfare or dat a integrity ) may be reported to the IRB at 
continuing review, using a protocol deviation log. The investigator  is responsible for knowing and 
adhering to the  reviewing IRB requirements.  
 
10.1.[ADDRESS_1090349]  POLICY  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.[ADDRESS_1090350].  
 
10.2 ADDITIONAL CONSIDERA TIONS  
 
Not applicable.  
 
  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  45 
 10.3 ABBREVIATIONS  
 
Aβ Amyloid -beta  
AD Alzheimer’s Disease  
ADAS -cog Alzheimer's Disease Assessment Scale -cognitive subscale  
ADCOMS  AD Composite Score  
AE Adverse Event  
APTT  Activated Partial Thromboplastin Time  
CBC Complete Blood Count  
CDR-SB Clinical Dementia Rating Sc ale Sum of Boxes  
CFR Code of Federal Regulations  
Cho Choline  
CMP  Comprehensive Metabolic Panel  
CoC Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CRF Case Report Form  
Cr Creatine  
CSM  Clinical Supplies Management H oldings, I nc. 
CTCAE  Common Terminology Criteria for Adverse Events  
DARA -SC Daratumumab Subcutaneous  
DP Drug Product  
ECG Electrocardiogram  
eCRF  Electronic Case Report Form  
EU European Union  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
GDS  Geriatric Depression Scale  
GLP Good Laboratory Practices  
GMP  Good Manufacturing Practices  
HBcAb  Hepatitis B Core Antibody  
HBsAg  Hepatitis B Surface Antigen  
HBV  Hepatitis B Virus 
HCP Health Care Provider  
HCV  Hepatitis C Virus  
HCVAb  Hepatitis C  Virus Antibody  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HIVAg/Ab  Human Immunodeficiency Virus  Antigen/Antibody  
1H-MRS  Proton Magnetic Resonance Spectroscopy  
IB Investigator’s Brochure  
ICF Informed C onsent Form  
ICH International Conference on Harmonisation   
IgG1κ  Immunoglobulin G1 K appa  
IND Investigational New Drug Application  
INR International Normalized Ratio  
IRB Institutional  Review Board  
IRR Infusion -Related Reaction  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  46 
 ISM Independent Safety Monitor  
IV Intravenous  
mAb  Monoclonal Antibody  
MHIS  Modified Hachinski Ischemia Score  
mI Myo -Inositol  
mL Milliliter  
MMSE  Mini -Mental State Examination  
MOP  Manual of Procedures  
MRI Magnetic Resonance Imaging  
NAA  N-Acetylaspartate  
NaCl  Sodium Chlor ide 
NCI National Cancer Institute  
NIA-AA National Institute on Aging -Alzheimer’s Association  
OHRP  Office for Human Research Protections  
ORR  Overall Response R ate 
PD Progressive Disease  
PFS Progression -Free Survival  
PI [INVESTIGATOR_790959]20  Recombinant human hyaluronidase  
RMANOVA  Repeated Measures Analysis of V ariance  
RT Room Temperature  
SAE Serious Advers e Event  
SC Subcutaneous  
SoA Schedule of Activities  
SOP Standard Operating Procedure  
TEAE  Treatment -emergent adverse event  
TSH Thyroid -Stimulating Hormone  
UP Unanticipated Problem  
US [LOCATION_002]  
VGPS  Very Good Partial Response  
 
  
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  47 
 10.4 PROTOCOL  AMENDME NT HISTORY  
 
 
Version  Date  Description of Change   Brief Rationale  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  48 
 11 REFERENCES  
 
Askoy P, et al. Regulation of SIRT 1 mediated NAD dependent d eacetylation: a novel role for the 
multifunctional enzyme CD38. Biochem Biophys Res Commun. [ADDRESS_1090351] 13;349(1):353 -9. PMID: 
16935261 DOI: 10.1016/j.bbrc.2006.08.066  
 
Blacher E, et al. Alzheimer's disease pathology is attenuated in a CD38 -deficient mouse mo del. Ann 
Neurol. 2015 Jul;78(1):88 -103.  PMID: 25893674 DOI: 10.1002/ana.[ZIP_CODE]  
 
Camacho -Pereira J, et al. CD38 dictates age -related NAD decline and mitochondrial dysfunction through 
an SIRT3 -dependent m echanism. Cell Metab. 2016 Jun 14;23(6):1127 -1139. PMID : 27304511 DOI: 
10.1016/j.cmet.2016.05.006  
 
Chari A, et al. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: 
part 2 safety and efficacy update of the open -label, multicenter, phase 1b study (PAVO) [abstract]. 
Blood . 2018;1 32(suppl 1):Abstract 1995.  
 
Folstein MF, et al. "Mini -mental state". A practical method for grading the cognitive state of patients for 
the clinician.  J Psychiatr Res. 1975 Nov;12(3):189 -98. PMID: 1202204  
 
Heneka MT, et al. Neuroinflammation in Alzheimer's  disease.  Lancet Neurol. 2015 Apr;14(4):388 -405. 
PMID: 25792098 DOI: 10.1016/S1474 -4422(15)[ZIP_CODE] -5 
 
Hughes CP, et al. A new clinical scale for the staging of dementia.  Br J Psychiatry. 1982 Jun;140:566 -72. 
PMID: 7104545  
 
Imai S, Guarante L. NAD+ and sirtui ns in aging and disease. Trends Cell Biol. 2014 Aug;24(8):464 -71. 
PMID: 24786309 DOI: 10.1016/j.tcb.2014.04.002  
 
Krejcik J, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T -cell expansion, and 
skews T -cell repertoire in multiple myelom a. Blood. 2016 Jul 21;128(3):384 -94. PMID: 27222480 DOI: 
10.1182/blood -[ADDRESS_1090352]. 2006;21(1):40 –43. PMID: 16254429 DOI: 10.1159/000089218  
 
May o L, et al. Dual role of CD38 in microglial activation and activation -induced cell death. J Immunol. 
2008 Jul 1;181(1):92 -103. PMID: 18566373 DOI:https://doi.org/10.4049/jimmunol.181.1.92  
 
McKhann GM, et al. The diagnosis of dementia due to Alzheimer’s dis ease:  Recommendations from the 
National Institute on Aging -Alzheimer’s  Association workgroups on diagnostic guidelines for Alzheimer’s 
disease . Alzheimers Dement. 2011 May;7(3):263 -9. PMID: 21514250 DOI: 10.1016/j.jalz.2011.03.005.  
 
An open -label, pi[INVESTIGATOR_790937]'s disease  Version 1.1 
Protocol #54767414ALZ001  25 April 2019  
 
DARZAD Protocol – Version 1.1    25 APR 2019  49 
 Perez Ortiz JM, Swerdlo w RH. Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis 
and novel therapeutic opportunities.  Br J Pharmacol. 2019 Jan 24.  [Epub ahead of print] PMID: 30675901 
DOI: 10.1111/bph.[ZIP_CODE]  
 
Raina P, et al. Effectiveness of cholinesterase inhib itors and memantine for treating dementia: evidence 
review for a clinical practice guideline.  Ann Intern Med. 2008 Mar 4;148(5):379 -97. PMID: 18316756  
 
Rockwood K, et al. The clinical meaningfulness of ADAS -Cog changes in Alzheimer's disease patients 
treat ed with donepezil in an open -label trial. BMC Neurol. 2007 Aug 30;7:26. PMID: 17760991 DOI: 
10.1186/1471 -2377 -7-26 
 
Rosen WG , et al. Pathological verification of ischemic score in differentiation of dementias.  Ann Neurol. 
1980 May;7(5):486 -8. PMID: 7396427  DOI: 10.1002/ana.410070516  
 
Rosen WG, et al. A new rating scale for Alzheimer's disease.   Am J Psychiatry. 1984 Nov;141(11):1356 -
64. PMID: 6496779 DOI: 10.1176/ajp.141.11.1356  
 
Sano M, et al. Adding delayed recall to the Alzheimer Disease Assessment Scale  is useful in studies of 
mild cognitive impairment but not Alzheimer disease.  Alzheimer Dis Assoc Disor d. 2011 Apr -
Jun;25(2):122 -7. DOI : 10.1097/WAD.0b013e3181f883b7  
 
Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development  of a shorter  
version. Clin Gerontol. 1986 June;5(1/2):165 -173.  
 
Usmani  SZ, et al. Open -label, multicenter, dose escalation P hase 1b study to assess the subcutaneous 
delivery of daratumumab in patients (pts) with relapsed or refractory multiple m yeloma (PA VO). Blood.  
2016 128:1149  
 
Vercruyssen M , et al.  The daratumumab c rosses the blood brain b arrier . Clinical Lymphoma, Myeloma 
and Leukemia . 2018; 18:S289  
 
Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015 Dec 4;350(6265):1208 -13. 
PMID : 26785480 DOI: 10.1126/science.aac4854  
 
Wang J, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.  J Neurol 
Neurosurg Psychiatry 2016;87:993 -999.  PMID: 27010616 PMCID: PMC5013117 DOI: 10.1136/jnnp -2015 -
312383  
 
Zhang R, et al. Systemic immune system alterations in early stages of Alzheimer's disease. J 
Neuroimmunol. 2013 Mar 15;256(1 -2):38 -42. PMID: 23380586 DOI: 10.1016/j.jneuroim.2013.01.002  
 
 